

COMPANY PROFILE

STRATEC SE (Frankfurt: SBS; Prime Standard, TecDAX, ISIN: DE0007289001) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners, especially the global players operating in the in vitro diagnostics industry, market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

SHARE CHART



SHAREHOLDER STRUCTURE

Investor group	Share
Fixed and family ownership (incl. investment companies)	41.47%
Treasury shares	0.06%
Institutional investors	36.72%
Retail investors including not identified institutional investors	21.75%
Total	100.00%

MANAGEMENT BOARD



Marcus Wolfinger



Dr. Robert Siegle



Dr. Claus Vielsack

SUPERVISORY BOARD

> Fred K. Brückner > Rainer Baule
> Prof. Dr. Stefanie Remmele

STOCK FUNDAMENTALS

ISIN	DE000STRA555
WKN	STRA55
Symbol	SBS
Reuters Code	SBSG.DE
Branch	DAXsector All Pharma & Healthcare
Transparency level	Prime Standard
Market segment	Regulated Market
Type of shares	Registered Shares
Capital stock	11,969,245 Euro
No. of shares	11,969,245
Initial listing	Aug 25, 1998
Stock exchanges	Xetra; Frankfurt am Main and other regional exchanges in Germany

FINANCIAL CALENDAR

Apr 11, 2019	Publication annual financial report
May 16, 2019	Publication quarterly statement (call-date Q1)
May 29, 2019	Annual General Meeting 2019
Aug 22, 2019	Publication half-yearly financial report
Nov 07, 2019	Publication quarterly statement (call-date Q3)
Nov 26, 2019	Analysts' Conference

ANNUAL FIGURES

IFRS (in € million)	2013	2014	2015	2016	2017
Sales	128.0	144.9	146.9	184.9	209.8
EBIT	19.5	24.1	26.9	32.2	35.5
EBIT as % of sales	15.2	16.6	18.3	17.4	16.9
Consolidated net income	15.5	19.8	22.1	25.4	27.9
Basic earnings per share (in €)	1.32	1.68	1.87	2.12	2.33
Dividend per share (in €)	0.60	0.70	0.75	0.77	0.80
Total employees	546	544	583	976	1,086
Total assets	117.8	137.8	158.9	258.0	263.8
Equity ratio (in %)	82.5	81.3	82.0	55.2	59.8
Free cash flow	13.5	32.9	17.3	-	-

QUARTERLY FIGURES

€ 000s ¹	2018			2017		
	Q1	H1	9M ²	Q1	H1	9M ³
Sales	41,600	90,165	134,627	49,510	100,723	149,418
Adjusted EBIT	4,293	8,846	17,044	6,870	12,816	24,513
Adjusted EBIT margin (%)	10.3	9.8	12.7	13.9	12.7	16.4
Adjusted consolidated net income ⁴	3,533	7,240	13,598	5,369	9,902	19,167
Adjusted earnings per share (€) ⁴	0.30	0.61	1.14	0.45	0.84	1.61

¹ For comparison purposes, adjusted figures exclude amortization resulting from purchase price allocations in the context of acquisitions and the associated reorganization expenses, as well as other non-recurring effects.

² In accordance with IFRS 9 and IFRS 15.

³ Not retrospectively restated to reflect IFRS 9 and IFRS 15 (modified retrospective approach). Retrospectively restated to reflect the classification of the nucleic acid preparation business as a discontinued operation in accordance with IFRS 5 and correction in accordance with IAS 8.41.

⁴ Results from continuing operations.

STRATEC SE

Gewerbestr. 37
75217 Birkenfeld
Deutschland

Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
info@strattec.com
www.strattec.com

Investor Relations

Phone: +49 7082 7916-6515
Fax: +49 7082 7916-9190
ir@strattec.com